Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal P… Read more
Chongqing Zhifei Bio Products (300122) - Total Assets
Latest total assets as of September 2025: CN¥46.39 Billion CNY
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) holds total assets worth CN¥46.39 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chongqing Zhifei Bio Products - Total Assets Trend (2007–2024)
This chart illustrates how Chongqing Zhifei Bio Products’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chongqing Zhifei Bio Products - Asset Composition Analysis
Current Asset Composition (December 2024)
Chongqing Zhifei Bio Products's total assets of CN¥46.39 Billion consist of 82.7% current assets and 17.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.4% |
| Accounts Receivable | CN¥16.28 Billion | 32.6% |
| Inventory | CN¥22.22 Billion | 44.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.72 Billion | 3.5% |
| Goodwill | CN¥19.28 Million | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Chongqing Zhifei Bio Products's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chongqing Zhifei Bio Products's current assets represent 82.7% of total assets in 2024, a decrease from 86.1% in 2007.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, down from 41.4% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 44.5% of total assets.
Chongqing Zhifei Bio Products Competitors by Total Assets
Key competitors of Chongqing Zhifei Bio Products based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Chongqing Zhifei Bio Products - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Chongqing Zhifei Bio Products generates 0.52x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Chongqing Zhifei Bio Products generates $ 4.04 in net profit.
Chongqing Zhifei Bio Products - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.80 | 2.10 | 1.69 |
| Quick Ratio | 1.23 | 1.14 | 1.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥23.23 Billion | CN¥ 23.81 Billion | CN¥ 4.72 Billion |
Chongqing Zhifei Bio Products - Advanced Valuation Insights
This section examines the relationship between Chongqing Zhifei Bio Products's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.32 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -0.6% |
| Total Assets | CN¥49.91 Billion |
| Market Capitalization | $2.19 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Chongqing Zhifei Bio Products's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Chongqing Zhifei Bio Products's assets decreased by 0.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Chongqing Zhifei Bio Products (2007–2024)
The table below shows the annual total assets of Chongqing Zhifei Bio Products from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥49.91 Billion | -0.64% |
| 2023-12-31 | CN¥50.23 Billion | +32.18% |
| 2022-12-31 | CN¥38.00 Billion | +26.48% |
| 2021-12-31 | CN¥30.05 Billion | +97.48% |
| 2020-12-31 | CN¥15.22 Billion | +39.05% |
| 2019-12-31 | CN¥10.94 Billion | +60.68% |
| 2018-12-31 | CN¥6.81 Billion | +65.86% |
| 2017-12-31 | CN¥4.11 Billion | +51.54% |
| 2016-12-31 | CN¥2.71 Billion | +1.04% |
| 2015-12-31 | CN¥2.68 Billion | -1.21% |
| 2014-12-31 | CN¥2.71 Billion | +4.89% |
| 2013-12-31 | CN¥2.59 Billion | +2.85% |
| 2012-12-31 | CN¥2.52 Billion | +4.66% |
| 2011-12-31 | CN¥2.40 Billion | +8.83% |
| 2010-12-31 | CN¥2.21 Billion | +326.48% |
| 2009-12-31 | CN¥518.02 Million | +32.79% |
| 2008-12-31 | CN¥390.10 Million | +17.40% |
| 2007-12-31 | CN¥332.30 Million | -- |